Traditional Chinese Medicine Integrated with Chemotherapy for Stage II-IIIA Patients with Non-Small-Cell Lung Cancer after Radical Surgery: A Retrospective Clinical Analysis with Small Sample Size

被引：30
作者：
Zhao, Xueyu [1 ,2 ,3 ,4 ]
Dai, Xiaojun [1 ,2 ,3 ,4 ,5 ]
Wang, Shanshan [5 ]
Yang, Ting [1 ,2 ,3 ,4 ]
Yan, Yan [1 ,2 ,3 ,4 ]
Zhu, Guang [1 ,2 ,3 ,4 ]
Feng, Jun [1 ,2 ,3 ,4 ]
Pan, Bo [1 ,2 ,3 ,4 ]
Sunagawa, Masataka [6 ]
Zhang, Xiaochun [5 ]
Qian, Yayun [1 ,2 ,3 ,4 ]
Liu, Yanqing [1 ,2 ,3 ,4 ]
机构：
[1] Yangzhou Univ, Dept Combined Tradit Chinese & Western Med, Sch Med, Yangzhou 225000, Jiangsu, Peoples R China
[2] Yangzhou Univ, Yangzhou Canc Res Inst, Yangzhou 225009, Jiangsu, Peoples R China
[3] Yangzhou Univ, Key Lab Tox Pathogens Based Therapeut Approaches, State Adm Tradit Chinese Med, Yangzhou 225000, Jiangsu, Peoples R China
[4] Yangzhou Univ, Med & Pharmaceut Inst, Yangzhou 225000, Jiangsu, Peoples R China
[5] Yangzhou Univ, Clin Tradit Chinese Med Coll, Yangzhou 225000, Jiangsu, Peoples R China
[6] Showa Univ, Sch Med, Dept Physiol, Tokyo 142, Japan
来源：
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE | 2018年 / 2018卷
基金：
中国国家自然科学基金;
关键词：
ADJUVANT CHEMOTHERAPY; POLYSACCHARIDES; STATISTICS; TERNATI; FORMULA;
D O I：
10.1155/2018/4369027
中图分类号：
R [医药、卫生];
学科分类号：
10 ;
摘要：
Objective. This study was designed to evaluate the clinical efficacy of combined traditional Chinese medicine (TCM) and conventional chemotherapy versus conventional chemotherapy in patients with stage II-IIIA non-small-cell lung cancer (NSCLC) after radical surgery. Methods. A retrospective cohort study was conducted in patients with stage II-IIIA NSCLC from Subei People's Hospital and Yangzhou Traditional Chinese Medicine Hospital in Yangzhou City of Jiangsu Province from 2012 to 2016. Patients were divided into two groups: the TCM user group (patients receiving treatment with integrated TCM and conventional chemotherapy) and the non-TCM user group (patients receiving conventional chemotherapy only). The two groups were compared for their median disease-free survival (DFS) and median overall survival (OS). Results. A total of 67 patients with stage II-IIIA NSCLC were enrolled between January 2012 and December 2016. The median DFS for the non-TCM user group was 601 days (95% confidence interval [CI], 375.7-826.3). The median DFS for TCM user group could not be calculated. However, log-rank analysis showed that the median survival time in the TCM user group was significantly longer than that of the non-TCM user group (P < 0.05). In addition, several significant risk factors were detected for predicting disease prognosis in patients with NSCLC, such as age, ECOG, lymphatic metastasis, and body mass index (BMI). For patients harboring these independent risk factors, the DFS of TCM user group was much longer than that of non-TCM user group (P < 0.05). Conclusion. Adjuvant therapy with TCM may reduce the rate of tumor recurrence and metastasis and prolong DFS of patients with stage II-IIIA NSCLC.
引用
收藏
页数：7
相关论文
共 20 条
[1]   Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer - An analysis of National Cancer Institute of Canada and intergroup trial JBR. 10 and a review of the literature [J].
Alam, N ;
Shepherd, FA ;
Winton, T ;
Graham, B ;
Johnson, D ;
Livingston, R ;
Rigas, J ;
Whitehead, M ;
Ding, K ;
Seymour, L .
LUNG CANCER, 2005, 47 (03) :385-394
[2]  
[Anonymous], 2015, EVID BASED COMPLEMEN
[3]   Oral Chinese herbal medicine (CHM) as an adjuvant treatment during chemotherapy for non-small cell lung cancer: A systematic review [J].
Chen, Sisi ;
Flower, Andrew ;
Ritchie, Andrew ;
Liu, Jianping ;
Molassiotis, Alex ;
Yu, He ;
Lewith, George .
LUNG CANCER, 2010, 68 (02) :137-145
[4]   Effects of Chinese Medicine as Adjunct Medication for Adjuvant Chemotherapy Treatments of Non-Small Cell Lung Cancer Patients [J].
Jiao, Lijing ;
Dong, Changsheng ;
Liu, Jiaxiang ;
Chen, Zhiwei ;
Zhang, Lei ;
Xu, Jianfang ;
Shen, Xiaoyong ;
Che, Jiaming ;
Yang, Yi ;
Huang, Hai ;
Li, Hegen ;
Sun, Jianli ;
Jiang, Yi ;
Mao, Zhujun ;
Chen, Peiqi ;
Gong, Yabin ;
Jin, Xiaolin ;
Xu, Ling .
SCIENTIFIC REPORTS, 2017, 7
[5]   Evidence-based Chinese medicine for cancer therapy [J].
Konkimalla, V. Badireenath ;
Efferth, Thomas .
JOURNAL OF ETHNOPHARMACOLOGY, 2008, 116 (02) :207-210
[6]   Over-expressed copper/zinc superoxide dismutase localizes to mitochondria in neurons inhibiting the angiotensin II-mediated increase in mitochondrial superoxide [J].
Li, Shumin ;
Case, Adam J. ;
Yang, Rui-Fang ;
Schultz, Harold D. ;
Zimmerman, Matthew C. .
REDOX BIOLOGY, 2014, 2 :8-14
[7]   Adjuvant chemotherapy of completely resected early stage non-small cell lung cancer (NSCLC) [J].
Liang, Ying ;
Wakelee, Heather A. .
TRANSLATIONAL LUNG CANCER RESEARCH, 2013, 2 (05) :403-410
[8]   Three advantages of using traditional Chinese medicine to prevent and treat tumor [J].
Ling, Chang-Quan ;
Yue, Xiao-Qiang ;
Ling, Chen .
JOURNAL OF INTEGRATIVE MEDICINE-JIM, 2014, 12 (04) :331-335
[9]  
Ma Wen-Hua, 2009, Zhong Xi Yi Jie He Xue Bao, V7, P315, DOI 10.3736/jcim20090404
[10]   Cancer treatment and survivorship statistics, 2016 [J].
Miller, Kimberly D. ;
Siegel, Rebecca L. ;
Lin, Chun Chieh ;
Mariotto, Angela B. ;
Kramer, Joan L. ;
Rowland, Julia H. ;
Stein, Kevin D. ;
Alteri, Rick ;
Jemal, Ahmedin .
CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (04) :271-289
12